Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS

J. A. Katzmann, R. Clark, R. A. Kyle, D. R. Larson, Terry M Therneau, L. J. Melton, J. T. Benson, C. L. Colby, Angela Dispenzieri, O. Landgren, Shaji K Kumar, A. R. Bradwell, James R Cerhan, S Vincent Rajkumar

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

We hypothesized that the suppression of uninvolved immunoglobulin in monoclonal gammopathy of undetermined significance (MGUS) as detected by suppression of the isotype-specific heavy and light chain (HLC-pair suppression) increases the risk of progression to malignancy. This approach required quantitation of individual heavy/light chains (for example, IgGλ in IgGκ MGUS patients). Of 1384 MGUS patients from Southeastern Minnesota seen at the Mayo Clinic from 1960 to 1994, baseline serum samples obtained within 30 days of diagnosis were available in 999 persons. We identified HLC-pair suppression in 27% of MGUS patient samples compared with 11% of patients with suppression of uninvolved IgG, IgA or IgM. HLC-pair suppression was a significant risk factor for progression (hazard ratio (HR), 2.3; 95% confidence interval (CI) 1.5-3.7; P<0.001). On multivariate analysis, HLC-pair suppression was an independent risk factor for progression to malignancy in combination with serum M-spike size, heavy chain isotype and free light chain ratio (HR, 1.8; 95% CI, 1.1-3.00; P=0.018). The finding that HLC-pair suppression predicts progression in MGUS and occurs several years before malignant transformation has implications for myeloma biology.

Original languageEnglish (US)
Pages (from-to)208-212
Number of pages5
JournalLeukemia
Volume27
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

Monoclonal Gammopathy of Undetermined Significance
Immunoglobulins
Light
Immunoglobulin G
Confidence Intervals
Serum
Immunoglobulin A
Immunoglobulin M
Neoplasms
Multivariate Analysis

Keywords

  • heavy/light
  • MGUS
  • multiple myeloma
  • prognosis
  • suppression

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS. / Katzmann, J. A.; Clark, R.; Kyle, R. A.; Larson, D. R.; Therneau, Terry M; Melton, L. J.; Benson, J. T.; Colby, C. L.; Dispenzieri, Angela; Landgren, O.; Kumar, Shaji K; Bradwell, A. R.; Cerhan, James R; Rajkumar, S Vincent.

In: Leukemia, Vol. 27, No. 1, 01.2013, p. 208-212.

Research output: Contribution to journalArticle

Katzmann, J. A. ; Clark, R. ; Kyle, R. A. ; Larson, D. R. ; Therneau, Terry M ; Melton, L. J. ; Benson, J. T. ; Colby, C. L. ; Dispenzieri, Angela ; Landgren, O. ; Kumar, Shaji K ; Bradwell, A. R. ; Cerhan, James R ; Rajkumar, S Vincent. / Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS. In: Leukemia. 2013 ; Vol. 27, No. 1. pp. 208-212.
@article{550b88a664bb4a2783fe35306d0be581,
title = "Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS",
abstract = "We hypothesized that the suppression of uninvolved immunoglobulin in monoclonal gammopathy of undetermined significance (MGUS) as detected by suppression of the isotype-specific heavy and light chain (HLC-pair suppression) increases the risk of progression to malignancy. This approach required quantitation of individual heavy/light chains (for example, IgGλ in IgGκ MGUS patients). Of 1384 MGUS patients from Southeastern Minnesota seen at the Mayo Clinic from 1960 to 1994, baseline serum samples obtained within 30 days of diagnosis were available in 999 persons. We identified HLC-pair suppression in 27{\%} of MGUS patient samples compared with 11{\%} of patients with suppression of uninvolved IgG, IgA or IgM. HLC-pair suppression was a significant risk factor for progression (hazard ratio (HR), 2.3; 95{\%} confidence interval (CI) 1.5-3.7; P<0.001). On multivariate analysis, HLC-pair suppression was an independent risk factor for progression to malignancy in combination with serum M-spike size, heavy chain isotype and free light chain ratio (HR, 1.8; 95{\%} CI, 1.1-3.00; P=0.018). The finding that HLC-pair suppression predicts progression in MGUS and occurs several years before malignant transformation has implications for myeloma biology.",
keywords = "heavy/light, MGUS, multiple myeloma, prognosis, suppression",
author = "Katzmann, {J. A.} and R. Clark and Kyle, {R. A.} and Larson, {D. R.} and Therneau, {Terry M} and Melton, {L. J.} and Benson, {J. T.} and Colby, {C. L.} and Angela Dispenzieri and O. Landgren and Kumar, {Shaji K} and Bradwell, {A. R.} and Cerhan, {James R} and Rajkumar, {S Vincent}",
year = "2013",
month = "1",
doi = "10.1038/leu.2012.189",
language = "English (US)",
volume = "27",
pages = "208--212",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS

AU - Katzmann, J. A.

AU - Clark, R.

AU - Kyle, R. A.

AU - Larson, D. R.

AU - Therneau, Terry M

AU - Melton, L. J.

AU - Benson, J. T.

AU - Colby, C. L.

AU - Dispenzieri, Angela

AU - Landgren, O.

AU - Kumar, Shaji K

AU - Bradwell, A. R.

AU - Cerhan, James R

AU - Rajkumar, S Vincent

PY - 2013/1

Y1 - 2013/1

N2 - We hypothesized that the suppression of uninvolved immunoglobulin in monoclonal gammopathy of undetermined significance (MGUS) as detected by suppression of the isotype-specific heavy and light chain (HLC-pair suppression) increases the risk of progression to malignancy. This approach required quantitation of individual heavy/light chains (for example, IgGλ in IgGκ MGUS patients). Of 1384 MGUS patients from Southeastern Minnesota seen at the Mayo Clinic from 1960 to 1994, baseline serum samples obtained within 30 days of diagnosis were available in 999 persons. We identified HLC-pair suppression in 27% of MGUS patient samples compared with 11% of patients with suppression of uninvolved IgG, IgA or IgM. HLC-pair suppression was a significant risk factor for progression (hazard ratio (HR), 2.3; 95% confidence interval (CI) 1.5-3.7; P<0.001). On multivariate analysis, HLC-pair suppression was an independent risk factor for progression to malignancy in combination with serum M-spike size, heavy chain isotype and free light chain ratio (HR, 1.8; 95% CI, 1.1-3.00; P=0.018). The finding that HLC-pair suppression predicts progression in MGUS and occurs several years before malignant transformation has implications for myeloma biology.

AB - We hypothesized that the suppression of uninvolved immunoglobulin in monoclonal gammopathy of undetermined significance (MGUS) as detected by suppression of the isotype-specific heavy and light chain (HLC-pair suppression) increases the risk of progression to malignancy. This approach required quantitation of individual heavy/light chains (for example, IgGλ in IgGκ MGUS patients). Of 1384 MGUS patients from Southeastern Minnesota seen at the Mayo Clinic from 1960 to 1994, baseline serum samples obtained within 30 days of diagnosis were available in 999 persons. We identified HLC-pair suppression in 27% of MGUS patient samples compared with 11% of patients with suppression of uninvolved IgG, IgA or IgM. HLC-pair suppression was a significant risk factor for progression (hazard ratio (HR), 2.3; 95% confidence interval (CI) 1.5-3.7; P<0.001). On multivariate analysis, HLC-pair suppression was an independent risk factor for progression to malignancy in combination with serum M-spike size, heavy chain isotype and free light chain ratio (HR, 1.8; 95% CI, 1.1-3.00; P=0.018). The finding that HLC-pair suppression predicts progression in MGUS and occurs several years before malignant transformation has implications for myeloma biology.

KW - heavy/light

KW - MGUS

KW - multiple myeloma

KW - prognosis

KW - suppression

UR - http://www.scopus.com/inward/record.url?scp=84873569295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873569295&partnerID=8YFLogxK

U2 - 10.1038/leu.2012.189

DO - 10.1038/leu.2012.189

M3 - Article

C2 - 22781594

AN - SCOPUS:84873569295

VL - 27

SP - 208

EP - 212

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 1

ER -